EMA Alerts Healthcare Professionals on Respreeza Vial Integrity Issues

The European Medicines Agency (EMA) has issued a Direct Healthcare Professional Communication regarding Respreeza (human alpha1-proteinase inhibitor). The alert informs healthcare professionals about potential risks of missed doses and infection due to compromised vial integrity, emphasizing the need for vigilance to ensure patient safety.